Meanwhile, earnings before interest, tax, depreciation, and amortisation (EBITDA) surged multifold to ₹128 crore, reflecting ...

Its revenue from operations during the reported quarter stood at Rs 721 crore. This marks a rise of nearly 3 percent from the Rs 701 crore revenue from operations reported in Q3 of FY24.

Zaynich could play a key role in treating patients suffering from complicated urinary tract infections caused by ...

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...

No.: WOCK/SEC/SE/2024-25/086 dated 3rd February, 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 7th February, 2025, inter-alia, have approved ...

Wockhardt share price jumped as much as 4 per cent in early trade on Monday, January 13, defying weak market sentiment. Wockhardt shares opened at ₹1,375.05 against their previous close of ...

What drove Wockhardt share price today? Wockhardt share price jumped in a weak market after it announced through an exchange filing that a life-saving antibiotic developed by it achieves over 97 ...

Regulations, 2015, read with Regulation 173 (A) of the SEBI ( Issue of Capital and Disclosure Requirements) Regulations, 2018, please find attached Monitoring Agency Reports towards utilisation of ...

The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults ...

Wockhardt's Zaynich, an investigational antibiotic, has been under evaluation for its efficacy in treating complicated ...